Laurie Sehn, MD, on Lenalidomide Plus Rituximab in Previously Untreated Mantle Cell Lymphoma
2014 ASH Annual MeetingLaurie Sehn, MD, of the BC Cancer Agency, on abstract 625, “Sustained Remission With the Combination Biologic Doublet of Lenalidomide Plus Rituximab as Initial Treatment for Mantle Cell Lymphoma: A Multicenter Phase II Study Report,” presented by Jia Ruan, MD, PhD.
Related Videos
Bertrand Coiffier, MD, PhD, on the Phase III LyMa Trial
Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 146, “
Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 289,
Richard M. Stone, MD, of Dana-Farber Cancer Institute, offers his thoughts on abstract 7,
Julie M. Vose, MD, MBA, FASCO, on Nivolumab in Relapsed/Refractory Hodgkin Lymphoma
Richard M. Stone, MD, on the UK NCRI AML17 Trial
Matthew Lunning, DO, on Ublituximab Plus TGR-1202 in Lymphoma
Matthew Lunning, DO, of the University of Nebraska Medical Center, on abstract 801, “Ublituxima...
Bertrand Coiffier, MD, PhD, on the RO-CHOP Study
Bertrand Coiffier, MD, PhD, of Centre Hospitalier Lyon-Sud, offers his thoughts on abstract 504,
